Xcout Intel
CureGene Pharmaceutical
Shanghai CureGene Pharmaceutical Co., Ltd. is a biopharmaceutical company founded in Zhangjiang, Shanghai, in 2018. It specializes in developing state-of-the-art medications and has built a globally leading targeted prodrug platform.
Subscribe to see CureGene Pharmaceutical’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CureGene Pharmaceutical at a glance
CureGene Pharmaceutical is a pharmaceuticals company headquartered in China. It has raised at least $60.8M across the 4 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series B, raised $47M in May 2026. Xcout tracks 1 named person at CureGene Pharmaceutical, including Gongxin He (Founder and CEO).
CureGene Pharmaceutical leadership
- Gongxin HeFounder and CEO
CureGene Pharmaceutical funding rounds
At least $60.8M raised across the 4 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $47M | 6 named | |
| Series B | $13.8M | 6 named | |
| — | Undisclosed | 5 named | |
| Series B | Undisclosed | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
CureGene Pharmaceutical competitors
A few of CureGene Pharmaceutical's closest competitors — see the full list of competitors and alternatives →
Danqing Pharmaceuticals is a pharmaceutical company headquartered in Beijing with a U.S. subsidiary in Boston. The company focuses on first-in-class drug discovery and development in oncology, targeting therapeutic areas such as breast, gynecological, and gastrointestinal cancers.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Cao Pharmaceuticals Inc. develops anti-cancer drugs utilizing natural anti-cancer compounds. The company focuses on research, product pipelines, and developing lead drug candidates for cancer treatment.
Anagenex is a biotechnology company that uses high-throughput experimentation, functional screening, and machine learning to discover small-molecule drug candidates. It focuses on challenging drug targets and works with biopharmaceutical companies as well as developing its own therapeutic programs.
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Get CureGene Pharmaceutical's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CureGene Pharmaceutical in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access